<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03700957</url>
  </required_header>
  <id_info>
    <org_study_id>73</org_study_id>
    <nct_id>NCT03700957</nct_id>
  </id_info>
  <brief_title>The Impact of Docosahexaenoic Acid on the Prevention of Necrotizing Enterocolitis in Preterm Neonates</brief_title>
  <official_title>A Clinical Study on the Impact of Docosahexaenoic Acid on the Prevention of Necrotizing Enterocolitis in Preterm Neonates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess the efficacy of Docosahexaenoic Acid in reducing the incidence of
      necrotizing enterocolitis in premature infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The efficacy of Docosahexaenoic Acid in reducing the incidence of necrotizing enterocolitis
      in preterm neonates will be evalutaed through measuring its immune-modulatory effect on
      proinflammatory cytokines.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2018</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Docosahexaenoic Acid in reducing the incidence of Necrotizing Enterocolitis in premature infants.</measure>
    <time_frame>10 days</time_frame>
    <description>Monitoring the change in the serum levels of Interleukin-1 beta</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Necrotizing Enterocolitis</condition>
  <arm_group>
    <arm_group_label>Docosahexaenoic Acid Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>participants will recieve 100 milligrams of Docosahexaenoic Acid per day for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>participants will recieve placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Docosahexaenoic Acid</intervention_name>
    <description>100 milligrams of Docosahexaenoic Acid</description>
    <arm_group_label>Docosahexaenoic Acid Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Preterm neonates having a gestational age equal or less than 34 weeks at birth.

          -  Weight (less than or equal 1.500 KG)

          -  Clinically stable to begin enteral feeding

        Exclusion Criteria:

          -  Persistent bleeding at any level.

          -  Receiving medication to avoid coagulation.

          -  Persistent vomiting.

          -  Gastrointestinal malformations.

          -  Mother taking Omega-3 supplements and planning to breastfeed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dina Abou El Fadl, Msc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Future University in Egypt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dina Abou El Fadl, Msc.</last_name>
    <phone>201005442855</phone>
    <email>dkhaled69@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yasmine Farid, MD</last_name>
    <phone>201001449558</phone>
    <email>Yasmin_Aly_Farid@hotmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Shulhan J, Dicken B, Hartling L, Larsen BM. Current Knowledge of Necrotizing Enterocolitis in Preterm Infants and the Impact of Different Types of Enteral Nutrition Products. Adv Nutr. 2017 Jan 17;8(1):80-91. doi: 10.3945/an.116.013193. Print 2017 Jan. Review.</citation>
    <PMID>28096129</PMID>
  </reference>
  <reference>
    <citation>Baack ML, Puumala SE, Messier SE, Pritchett DK, Harris WS. Daily Enteral DHA Supplementation Alleviates Deficiency in Premature Infants. Lipids. 2016 Apr;51(4):423-33. doi: 10.1007/s11745-016-4130-4. Epub 2016 Feb 4.</citation>
    <PMID>26846324</PMID>
  </reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 29, 2018</study_first_submitted>
  <study_first_submitted_qc>October 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>October 6, 2018</last_update_submitted>
  <last_update_submitted_qc>October 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Future University in Egypt</investigator_affiliation>
    <investigator_full_name>Dina Khaled Mohamed Abou El Fadl</investigator_full_name>
    <investigator_title>Assistant Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enterocolitis</mesh_term>
    <mesh_term>Enterocolitis, Necrotizing</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

